8月18日，Twist Bioscience盘中上涨5.07%，报124.49美元/股，成交额9744.33万美元。
消息面上，公司8月3日发布的第三季度财报显示营收1.184亿美元，超出市场预期的1.145亿美元；同时公司给出第四季度营收指引1.23亿至1.24亿美元，大幅高于市场预估的1.174亿美元。公司连续第14个季度实现营收增长，CEO明确预期本季度将实现调整后EBITDA盈亏平衡。作为AI制药产业链中DNA合成环节的核心供应商，公司深度绑定AI药物发现需求，蛋白业务增速显著，叠加完成3亿美元增发扩充产能，基本面持续改善推动股价在前期回调后反弹。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.